Zhitong Finance App News, Diakang Shiyun-B (02592.HK) issued an announcement. CBT-001 is the top line result of the 3rd phase of the study as a potential treatment for pterygium. Both main endpoints were statistically significant. Comparing the length of conjunctival hyperemia at month 3 and pterygium lesion length at month 12 in the placebo control group, the two doses of CBT-001 showed a highly statistically significant improvement. These results mark the first time that a drug has shown a therapeutic effect on pterygium disease by statistically significantly improving congestion and lesion size. Other analyses are ongoing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.